Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 11, 2015, 115 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $183.00 to $317,250,000.00.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Hawkins Jeffrey Alan, who is SVP, Global Marketing & PM at GenMark Diagnostics, sold 6,832 shares at $12.01 on March 11, 2015. Following this transaction, the SVP, Global Marketing & PM owned 117,628 shares meaning that the stake was reduced by 5.49% with the 6,832-share transaction.

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 10,902 shares at $11.92 on March 11, 2015. Following this transaction, the SVP, Human Resources owned 184,032 shares meaning that the stake was reduced by 5.59% with the 10,902-share transaction.

Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 10,021 shares at $11.93 on March 11, 2015. Following this transaction, the SVP, North American Com. Ops. owned 183,337 shares meaning that the stake was reduced by 5.18% with the 10,021-share transaction.

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 3,310 shares at $12.06 on March 11, 2015. Following this transaction, the SVP, International owned 61,715 shares meaning that the stake was reduced by 5.09% with the 3,310-share transaction.

Stier Eric, who is SVP & General Counsel at GenMark Diagnostics, sold 4,665 shares at $12.04 on March 11, 2015. Following this transaction, the SVP & General Counsel owned 41,278 shares meaning that the stake was reduced by 10.15% with the 4,665-share transaction.

Kagnoff Michael, who is Director at GenMark Diagnostics, bought 5,000 shares at $11.84 on March 11, 2015. Following this transaction, the Director owned 8,938 shares meaning that the stake was boosted by 126.97% with the 5,000-share transaction.

The shares most recently traded at $12.57, up $0.73, or 5.81% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares sold: 696
  • 12-Week # shares sold: 5,554
  • 24-Week # shares sold: 25,938

The average volume for GenMark Diagnostics has been 128,300 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $493.4 million and is part of the health care sector and health services industry. Shares are down 13.37% year-to-date as of the close of trading on Wednesday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 4 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PTC Therapeutics (PTCT) - FREE Research Report

Peltz Stuart Walter, who is Chief Executive Officer at PTC Therapeutics, sold 47,201 shares at $70.74 on March 11, 2015. Following this transaction, the Chief Executive Officer owned 47,200 shares meaning that the stake was reduced by 50% with the 47,201-share transaction.

The shares most recently traded at $74.82, up $4.08, or 5.46% since the insider transaction. Historical insider transactions for PTC Therapeutics go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 9,000
  • 24-Week # shares bought: 711,676
  • 24-Week # shares sold: 50,501

The average volume for PTC Therapeutics has been 498,200 shares per day over the past 30 days. PTC Therapeutics has a market cap of $2.4 billion and is part of the health care sector and drugs industry. Shares are up 44.04% year-to-date as of the close of trading on Wednesday.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Currently, there are 7 analysts who rate PTC Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PTCT - FREE

TheStreet Quant Ratings

rates PTC Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full

PTC Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alamo Group (ALG) - FREE Research Report

Pummell Richard D, who is VP & Mgr Agricultural Div at Alamo Group, sold 11,000 shares at $55.41 on March 11, 2015. Following this transaction, the VP & Mgr Agricultural Div owned 1,000 shares meaning that the stake was reduced by 91.67% with the 11,000-share transaction.

The shares most recently traded at $56.56, up $1.15, or 2.03% since the insider transaction. Historical insider transactions for Alamo Group go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,300
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 2,300
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 172,600

The average volume for Alamo Group has been 52,700 shares per day over the past 30 days. Alamo Group has a market cap of $628.4 million and is part of the industrial goods sector and industrial industry. Shares are up 16.14% year-to-date as of the close of trading on Wednesday.

Alamo Group Inc. designs, manufactures, and sells agricultural equipment and infrastructure maintenance equipment for governmental and industrial use primarily in the United States, the United Kingdom, France, Canada, and Australia. The stock currently has a dividend yield of 0.58%. The company has a P/E ratio of 16.2. Currently, there are 3 analysts who rate Alamo Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALG - FREE

TheStreet Quant Ratings

rates Alamo Group as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

Alamo Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null